The positive outcome of the Phase 3 trial is a significant milestone for Verrica Pharmaceuticals, as it validates the efficacy and safety of their product, VP-102, and its market potential in Japan. The surge in stock price reflects investor optimism about the future revenue and growth prospects stemming from this development. The impact is direct and substantial, given the exclusive licensing agreement with Torii for the Japanese market.